128 related articles for article (PubMed ID: 38303355)
21. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
Zhang C; Friedman S; Mruthyunjaya P; Parikh R
Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
[TBL] [Abstract][Full Text] [Related]
22. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
23. Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment.
Rigault E; Lacas B; Glehen O; Smith D; Dupont-Bierre E; Guimbaud R; Malka D; Boige V; Fuerea A; Pignon JP; Ducreux M
Cancer Treat Res Commun; 2023; 34():100674. PubMed ID: 36565566
[TBL] [Abstract][Full Text] [Related]
24. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
[TBL] [Abstract][Full Text] [Related]
26. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
[TBL] [Abstract][Full Text] [Related]
28. [Two radically resected colorectal carcinoma cases with unresectable liver metastasis after adjuvant chemotherapy with bevacizumab].
Sugiyama M; Kakeji Y; Kubo N; Nakanoko T; Fujinaka Y; Ando K; Masuda T; Yagi K; Yoshinaga K; Saeki H; Endo K; Emi Y; Morita M; Maehara Y
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2169-71. PubMed ID: 20037359
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer.
Apsangikar PD; Chaudhry SR; Naik MM; Deoghare SB; Joseph J
Indian J Cancer; 2017; 54(3):535-538. PubMed ID: 29798953
[TBL] [Abstract][Full Text] [Related]
30. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents.
García-Alfonso P; Ferrer A; Gil S; Dueñas R; Pérez MT; Molina R; Capdevila J; Safont MJ; Castañón C; Cano JM; Lara R
Target Oncol; 2015 Dec; 10(4):453-65. PubMed ID: 25752908
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
33. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y; Lei K; Jia Y; Ni B; He Z; Bi M; Wang X; Shi J; Zhou M; Sun Q; Wang G; Chen D; Shu Y; Liu L; Guo Z; Liu Y; Yang J; Wang K; Xiao K; Wu L; Yi T; Sun D; Kang M; Ma T; Mao Y; Shi J; Tang T; Wang Y; Xing P; Lv D; Liao W; Luo Z; Wang B; Wu X; Zhu X; Han S; Guo Q; Liu R; Lu Z; Zhang J; Fang J; Hu C; Ji Y; Liu G; Lu H; Wu D; Zhang J; Zhu S; Liu Z; Qiu W; Ye F; Yu Y; Zhao Y; Zheng Q; Chen J; Pan Z; Zhang Y; Lian W; Jiang B; Qiu B; Zhang G; Zhang H; Chen Y; Chen Y; Duan H; Li M; Liu S; Ma L; Pan H; Yuan X; Yuan X; Zheng Y; Gao E; Zhao L; Wang S; Wu C
Cancer Commun (Lond); 2021 Sep; 41(9):889-903. PubMed ID: 34184418
[TBL] [Abstract][Full Text] [Related]
35. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
[TBL] [Abstract][Full Text] [Related]
36. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358
[TBL] [Abstract][Full Text] [Related]
37. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.
Moosmann N; Laessig D; Michaely HJ; Schulz C; Heinemann V
Onkologie; 2007 Oct; 30(10):509-12. PubMed ID: 17890890
[TBL] [Abstract][Full Text] [Related]
38. [Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.].
Danesi R; Cremolini C; Ciccarone F; Lorusso D
Recenti Prog Med; 2021 Jun; 112(6):444-453. PubMed ID: 34128936
[TBL] [Abstract][Full Text] [Related]
39. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
[TBL] [Abstract][Full Text] [Related]
40. [A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment].
Matsumoto R; Mori S; Toda H; Kita Y; Arigami T; Sasaki K; Kurahara H; Maemura K; Natsugoe S
Gan To Kagaku Ryoho; 2021 Feb; 48(2):223-225. PubMed ID: 33597364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]